Pentavalent Vaccine

Penbraya from the components of 2 meningococcal vaccines Trumenba (against group B) & Nimenrix (against A, C, W-135 and Y) is the first pentavalent vaccine developed by Pfizer.

The US Food and Drug Administration (FDA) approved Penbraya, the only vaccine that provides coverage against the five most common serogroups causing meningococcal disease in adolescents and young adults aged 10 through 25 years. The Centers for Disease Control and Prevention’s (CDC) advisers are scheduled to meet to discuss use of the vaccine.

Read the full article.